Amended Claims

1. **(currently amended)** A compound of **[[the]]** formula (I)**:**



(I)**,**

or a pharmaceutically acceptable salt or ester thereof, wherein:

G is selected from the group consisting of**:**

a) 

b) 

c) 

d) 

e) 

f) 
"R , and

g) 
R" ;

~~**wherein**~~

Q is NH or O**; [[and]]**

Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl, and phenyl-C_1-C_4-alkyl;





~~**wherein**~~

R' and R'' are independently H or C_1-C_4-alkyl;

~~02/18/2004 MAHMED1 00000140 09924732~~

~~01 FC:1252 420.00 OP~~

~~02/18/2004 MAHMED1 00000140 09924732~~

~~02 FC:1202 126.00 OP~~

B is C_1-C_4 alkyl or C_2-C_4 alkenyl;

A is selected from the group consisting of CH_2, O, $S(O)_p$ ~~wherein p is zero, 1 or 2~~, NH, ~~a group~~ CON(R'''), **and** ~~[[or]]~~ N(R''')CO; ~~wherein~~

p is zero, 1, or 2;

R''' is hydrogen or CH_3;

R_1 is selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3;

X is ~~[[(]]~~ C=O ~~[[)]~~$_m$ **wherein m is 0 or 1]] or a bond, except that X is C=O when G is:**



;

R_2 is selected from the group consisting of:

H; ~~[[,]]~~

C_1-C_4 alkyl; ~~[[,]]~~

C_3-C_7 cycloalkyl; ~~[[,]]~~

C_1-C_4-alkylcycloalkyl;

aryl ~~unsubstituted or~~ optionally substituted by one to three substituents independently selected from **the group consisting of** halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

aralkyl; and

a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, and isoxazolyl, wherein: ~~C_5-C_7 monocyclic heteroaryl ring having one to three heteroatoms selected from O, S, and N, unsubstituted or~~ **any such heteroaryl is** optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

Y is $(CH_2)_n$; ~~wherein~~

n is 1 or 2; **and**

R is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_2-C_4 alkenyl, C_2-C_4

alkynyl, aryl, **and** **[[or]]** aryl-C_1-C_4 alkyl. ~~**With the proviso that m cannot be 0 when G is:**~~

~~**a)**~~  ~~**wherein Q' is H and Q is O and X is $(C=O)_m$.**~~

2. **(currently amended)** A compound, **salt, or ester** according to claim 1, wherein:

G is selected from the group consisting of:

a)  ,

 ,

b)  ,

 ,

c)  ,

 , **and**



~~**wherein Q is NH or O and Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl, and phenyl-C_1-C_4-alkyl;**~~

~~b)~~ 



~~**wherein R' is independently H or C_1-C_4-alkyl;**~~

B is $(CH_2)_q$; ~~**wherein**~~

q is 2, 3, or 4; **and**

R_2 is: **[[a]]**

phenyl **optionally substituted** by one to three substituents independently selected from **the group consisting of** halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

aralkyl; or

pyridine ~~ring unsubstituted or~~ optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy.

~~With the proviso that m can not be 0 when G is:~~

~~a)~~  ~~wherein Q' is H and Q is O and X is $(C=O)_m$;~~

3. **(currently amended)** A compound, **salt, or ester** according to claim 1, wherein:

G is selected from the group consisting of:



B is $(CH_2)_q$; ~~wherein~~

q is 2, 3, or 4; **and**

R_2 is: **[[a]]**

a phenyl **optionally substituted** by one to three substituents independently selected from **the group consisting of** halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

aralkyl; or

pyridine ~~ring unsubstituted or~~ optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy.

4. **(currently amended)** The compound**, salt, or ester** as recited in claim 1**,** wherein the compound is selected from the group consisting of**:**

(4-phenyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; **and**

(4-methyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid**.** ~~;~~

~~**(4-cyclopropylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**~~

~~**(4-cyclopropylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**~~

~~(4-cyclopropylmethyl-6-{[5-(2-pyridinylamino)pentanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[3-(2-pyridinylamino)propanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[4-(2-pyridinylamino)butanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[5-(2-pyridinylamino)pentanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[3-(2-pyridinylamino)propanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[4-(2-pyridinylamino)butanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[5-(2-pyridinylamino)pentanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~[4-phenyl-6-{[2-(2-pyridinylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[3-(2-pyridinylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[4-(2-pyridinylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[2-(1H-imidazol-2-ylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

5. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of **a** **[[the]]** compound of **[[the]]** formula (I):



(I)

or a pharmaceutically acceptable salt or ester thereof, wherein:

G is selected from the group consisting of:

a) 

,

b) 

,

c) 

,

d) 

,

e) 

,

f) 

, **and**

g) 

;

~~**wherein**~~

Q is NH or O; **[[and]]**

Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl, and phenyl-C_1-C_4-alkyl;



~~wherein~~

R' and R'' are independently H or C_1-C_4-alkyl;

B is C_1-C_4 alkyl or C_2-C_4 alkenyl;

A is selected from the group consisting of CH_2, O, $S(O)_p$ ~~wherein p is zero, 1 or 2~~, NH, ~~a group~~ CON(R'''), **and** **[[or]]** N(R''')CO**;** ~~wherein~~

R''' is hydrogen or CH_3;

p is zero, 1 or 2;

R_1 is selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3;

X is **[[(]]** C=O **[[)$_m$ wherein m is 0 or 1]]** **or a bond, except that X is C=O when G is:**



R_2 is selected from the group consisting of**:**

H**;** **[[,]]**

C_1-C_4 alkyl**;** **[[,]]**

C_3-C_7 cycloalkyl**;** **[[,]]**

C_1-C_4-alkylcycloalkyl;

aryl ~~unsubstituted or~~ optionally substituted by one to three substituents independently selected from **the group consisting of** halogen, CF_3, C_1-C_4 alkyl, hydroxy**,** and C_1-C_4 alkoxy;

aralkyl; and

a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,

oxazolyl, and isoxazolyl, wherein: ~~C_5-C_7 monocyclic heteroaryl ring having one to three heteroatoms selected from O, S, and N, unsubstituted or~~ **any such heteroaryl is** optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

Y is $(CH_2)_n$; ~~wherein~~

n is 1 or 2; **and**

R is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, aryl, **and [[or]]** aryl-C_1-C_4 alkyl.

~~With the proviso that m can not be 0 when G is:~~

~~a)~~  ~~wherein Q' is H and Q is O and X is $(C=O)_m$;~~

6. **(currently amended)** A pharmaceutical composition of claim 5, wherein:

G is selected from the group consisting of:

a)  ,

 ,

b)  ,

 ,

c)  ,

 , **and**



~~wherein Q is NH or O and Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl, and phenyl-C_1-C_4-alkyl~~;





~~wherein R' is independently H or C_1-C_4-alkyl;~~

B is $(CH_2)_q$; ~~wherein~~

q is 2, 3, or 4; **and**

R_2 is: **[[a]]**

phenyl **optionally substituted** by one to three substituents independently selected from **the group consisting of** halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

aralkyl; or

pyridine ~~ring unsubstituted or~~ optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy.

~~With the proviso that m can not be 0 when G is:~~



~~a)~~ ~~wherein Q' is H and Q is O and X is $(C=O)_m$.~~

7. **(currently amended)** A pharmaceutical composition of claim 5, wherein:

G is selected from the group consisting of:



B is $(CH_2)_q$; ~~wherein~~

q is 2, 3, or 4; **and**

R_2 is: **[[a]]**

phenyl **optionally substituted** by one to three substituents independently selected from **the group consisting of** halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

aralkyl; or

pyridine ~~ring unsubstituted or~~ optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy.

8. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt ~~, prodrug~~ or ester thereof as recited in claim 5, wherein the compound is selected from the group consisting of:

(4-phenyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-

2-yl)acetic acid;

(4-methyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; **and**

(4-methyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid ~~;~~

~~(4-cyclopropylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-~~

~~2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-~~

~~benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~[4-phenyl-6-{[2-(2-pyridinylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[3-(2-pyridinylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[4-(2-pyridinylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[2-(1H-imidazol-2-ylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid~~.

9. **(currently amended)** A method for treating **a mammal having** a condition **treatable by inhibiting** ~~mediated by the~~ $\alpha_v\beta_3$ integrin**, wherein:** ~~in a mammal in need of such treatment, including a human, comprising~~

the method comprises administering to said mammal an effective $\alpha_v\beta_3$ inhibiting amount of a compound of **[[the]]** formula (I) **(or a pharmaceutically acceptable salt or ester thereof):**



(I);

~~**wherein:**~~

G is selected from the group consisting of**:**

a)  ;

b)  ;

c)  ;

d)  ;

e)  ;

f)  **, and**

g)  ;

~~**wherein**~~

Q is NH or O**;** **[[and]]**

Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl, and phenyl-C_1-C_4-alkyl;



~~**wherein**~~

R' and R'' are independently H or C_1-C_4-alkyl;

B is C_1-C_4 alkyl or C_2-C_4 alkenyl;

A is selected from the group consisting of CH_2, O, $S(O)_p$ ~~**wherein p is zero, 1 or 2**~~, NH, ~~**a group**~~ CON(R'''), **and** **[[or]]** N(R''')CO**;** ~~**wherein**~~

p is zero, 1, or 2;

R''' is hydrogen or CH_3;

R_1 is selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen,

and CF_3;

X is **[[(]]** C=O **[[)$_m$ wherein m is 0 or 1]]** **and a bond, except that X is C=O when G is:**



R_2 is selected from the group consisting of**:**

H**; [[,]]**

C_1-C_4 alkyl**; [[,]]**

C_3-C_7 cycloalkyl**; [[,]]**

C_1-C_4-alkylcycloalkyl;

aryl ~~**unsubstituted or**~~ optionally substituted by one to three substituents independently selected from **the group consisting of** halogen, CF_3, C_1-C_4 alkyl, hydroxy**,** and C_1-C_4 alkoxy;

aralkyl; and

a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, and isoxazolyl, wherein: ~~**C_5-C_7 monocyclic heteroaryl ring having one to three heteroatoms selected from O, S, and N, unsubstituted or**~~ **any such heteroaryl is** optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF_3, C_1-C_4 alkyl, hydroxy**,** and C_1-C_4 alkoxy;

Y is $(CH_2)_n$**;** ~~**wherein**~~

n is 1 or 2; **and**

R is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, aryl**, and [[or]]** aryl-C_1-C_4 alkyl. ~~**With the proviso that m cannot be 0 when G is:**~~

~~**a)**~~  ~~**wherein Q' is H and Q is O and X is $(C=O)_m$.**~~

10. **(currently amended)** The method of claim 9**,** wherein:

G is selected from the group consisting of:

a) 

b) 

c) 







, and



~~wherein Q is NH or O and Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl, and phenyl C_1-C_4-alkyl~~;





~~wherein R' is independently H or C_1-C_4-alkyl;~~

B is $(CH_2)_q$; ~~wherein~~

q is 2, 3, or 4; **and**

R_2 is: [[a]]

phenyl **optionally substituted** by one to three substituents independently selected from **the group consisting of** halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

aralkyl; or

pyridine ~~ring unsubstituted or~~ optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy.

~~**With the proviso that m can not be 0 when G is:**~~

~~**a)**~~  ~~**wherein Q' is H and Q is O and X is $(C=O)_m$;**~~

11. **(currently amended)** The method of claim 9, wherein:

G is selected from the group consisting of:



B is $(CH_2)_q$, ~~**wherein**~~

q is 2, 3, or 4; **and**

R_2 is: **[[a]]**

phenyl **optionally substituted** by one to three substituents independently selected from **the group consisting of** halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

aralkyl; or

pyridine ~~**ring unsubstituted or**~~ optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF_3, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy.

12. **(currently amended)** The method according to claim 9, wherein the compound is selected from the group consisting of:

(4-phenyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-

benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; **and**

(4-methyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid ~~;~~

~~(4-cyclopropylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[4-(2-pyridinylamino)butanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[5-(2-pyridinylamino)pentanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[3-(2-pyridinylamino)propanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[4-(2-pyridinylamino)butanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[5-(2-pyridinylamino)pentanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]-amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-benzoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-nicotinoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~[4-phenyl-6-{[2-(2-pyridinylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[3-(2-pyridinylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[4-(2-pyridinylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[2-(1H-imidazol-2-ylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;~~

~~[4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid~~.

13. **(currently amended)** The method according to claim 9~~,~~ wherein the condition

treated is bone resorption, osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, neoplasia (solid tumor growth), angiogenesis ~~including tumor angiogenesis~~, diabetic retinopathy, arthritis, psoriasis, **[[and]]** periodontal disease, or smooth muscle cell migration ~~including restenosis~~.

14. **(currently amended)** The method according to claim 12, wherein the condition treated is bone resorption, osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, neoplasia (solid tumor growth), angiogenesis ~~including tumor angiogenesis~~, diabetic retinopathy, arthritis, psoriasis, **[[and]]** periodontal disease, or smooth muscle cell migration ~~including restenosis~~.

15. **(currently amended)** A ~~combined~~ method of treatment of cancer or of controlling the growth of a neoplasm in a mammal suffering from cancer, ~~including a human,~~ said method comprising administering simultaneous, separately, or sequentially **the following agents in amounts and close enough together in time sufficient to produce a therapeutically useful effect:** **[[,]]**

1) a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable **salt** **[[salts]]** thereof; and

2) an additional antitumor agent ~~; in amounts and close enough together in time sufficient to produce a therapeutically useful effect~~.

16. **(original)** The method according to claim 15, wherein the additional antitumor agent is selected from the group consisting of an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.

17. **(currently amended)** A **combination pack** ~~product~~ containing a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, and an effective antineoplastic amount of additional antitumor agent as a combined preparation for simultaneous, separate, or sequential use in anti-cancer therapy.

18. **(currently amended)** The **combination pack** ~~**product**~~ according to claim 17, wherein the additional antitumor agent is selected from **the group consisting of** an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite, and an antineoplastic topoisomerase I inhibitor.

19. **(new)** The compound as recited in claim 1, wherein the compound is selected from the group consisting of:

(4-cyclopropylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-

1,4-benzoxazin-2-yl)acetic acid; and

(4-cyclohexylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

20. **(new)** The compound as recited in claim 1, wherein the compound is selected from the group consisting of:

(4-benzyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-benzoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

21. **(new)** The compound as recited in claim 1, wherein the compound is selected from the group consisting of:

(4-nicotinoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

[4-phenyl-6-{[2-(2-pyridinylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[3-(2-pyridinylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[4-(2-pyridinylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[2-(1H-imidazol-2-ylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid; and

[4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid.

22. **(new)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or ester thereof as recited in claim 5,

wherein the compound is selected from the group consisting of:

(4-cyclopropylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-cyclohexylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

23. **(new)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or ester thereof as recited in claim 5, wherein the compound is selected from the group consisting of:

(4-benzyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-

2-yl)acetic acid;

(4-benzyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-benzoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

24. **(new)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or ester thereof as recited in claim 5, wherein the compound is selected from the group consisting of:

(4-nicotinoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-

2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

[4-phenyl-6-{[2-(2-pyridinylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[3-(2-pyridinylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[4-(2-pyridinylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[2-(1H-imidazol-2-ylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid; and

[4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid.

25. **(new)** The method according to claim 9, wherein the compound is selected from the group consisting of:

(4-cyclopropylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-cyclohexylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

26. **(new)** The method according to claim 9, wherein the compound is selected from the group consisting of:

(4-benzyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-benzoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

27. **(new)** The method according to claim 9, wherein the compound is selected from the group consisting of:

(4-nicotinoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

[4-phenyl-6-{[2-(2-pyridinylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-

benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[3-(2-pyridinylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[4-(2-pyridinylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[2-(1H-imidazol-2-ylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid; and

[4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid.